Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP)

July 8, 2026 6:41 AM
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $80.00 price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments